<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284385</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-01670</org_study_id>
    <secondary_id>NCI-2017-01670</secondary_id>
    <secondary_id>10170</secondary_id>
    <secondary_id>10170</secondary_id>
    <secondary_id>UM1CA186689</secondary_id>
    <nct_id>NCT03284385</nct_id>
  </id_info>
  <brief_title>Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2</brief_title>
  <official_title>A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well adavosertib works in treating patients with&#xD;
      SETD2-deficient solid tumors that have spread to other places in the body&#xD;
      (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the objective response rate by Response Evaluation Criteria in Solid Tumors&#xD;
      (RECIST) 1.1 criteria of adavosertib (AZD1775) in advanced solid tumor malignancies other&#xD;
      than clear cell renal cell carcinoma with evidence of pathogenic loss of SETD2 using&#xD;
      next-generation sequencing panel.&#xD;
&#xD;
      II. To determine the objective response rate by RECIST 1.1 criteria of AZD1775 in clear cell&#xD;
      renal cell carcinoma with evidence of loss of SETD2 using next-generation sequencing panel.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the clinical benefit rate and duration of response of AZD1775 in&#xD;
      SETD2-deficient tumors other than clear cell renal cell carcinoma.&#xD;
&#xD;
      II. To determine the clinical benefit rate and duration of response of AZD1775 in&#xD;
      SETD2-deficient clear cell renal cell carcinoma subgroup.&#xD;
&#xD;
      III. To characterize the safety profile of AZD1775. IV. To determine whether H3K36me3&#xD;
      expression by immunohistochemical assay is associated with clinical outcomes.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive adavosertib orally (PO) once daily (QD) on days 1-5 and 8-12. Cycles repeat&#xD;
      every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The median duration of response will be descriptively reported using Kaplan-Meier product limit method along with 95% confidence interval. The objective response rate between cohorts will be compared using the chi-squared test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined as patients who experience either objective response or stable disease for &gt;= 6 months from start of study treatment. The clinical benefit rate across the entire study cohort will be descriptively reported along with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The median duration of response will be descriptively reported using Kaplan-Meier product limit method along with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be graded by Common Toxicity Criteria version 5.0, will be descriptively reported for the safety-evaluable population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H3K36me3 mark</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The median progression-free survival for each cohort will be determined using the Kaplan-Meier product limit method and compared between cohorts using the log-rank test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Locally Advanced Clear Cell Renal Cell Carcinoma</condition>
  <condition>Locally Advanced Malignant Solid Neoplasm</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <condition>Stage III Renal Cell Cancer AJCC v8</condition>
  <condition>Stage IV Renal Cell Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (adavosertib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adavosertib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (adavosertib)</arm_group_label>
    <other_name>AZD-1775</other_name>
    <other_name>AZD1775</other_name>
    <other_name>MK-1775</other_name>
    <other_name>MK1775</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cohort A: Histologically confirmed locally advanced or metastatic solid tumor&#xD;
             malignancy other than clear cell renal cell carcinoma with progression on at least one&#xD;
             prior systemic therapy and presence of pathogenic loss of SETD2 detected in tumor&#xD;
             tissue detected using a Clinical Laboratory Improvement Act (CLIA)-certified next&#xD;
             generation sequencing panel (e.g. UCSF500, FoundationOne)&#xD;
&#xD;
          -  Cohort B: Patients with histologically confirmed locally advanced or metastatic clear&#xD;
             cell renal cell carcinoma (with clear cell component on pathology), who have been&#xD;
             treated with at least one prior systemic therapy for locally advanced or metastatic&#xD;
             disease, including either tyrosine kinase inhibitor and/or immune checkpoint&#xD;
             inhibitor, with evidence of SETD2 mutation on CLIA-certified next generation&#xD;
             sequencing panel&#xD;
&#xD;
               -  All next generation sequencing (NGS) sequencing reports will be reviewed by the&#xD;
                  University of California at San Francisco (UCSF) Molecular Tumor Board to verify&#xD;
                  pathogenicity of SETD2 mutation. Each NGS report will be redacted for Protected&#xD;
                  Health Information (PHI) prior to submission from investigational site to UCSF&#xD;
                  MTB.&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1 criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits (WLN) or =&lt; 1.5 x upper limit of&#xD;
             normal (ULN) in patients with liver metastases; or total bilirubin =&lt; 3 x ULN with&#xD;
             direct bilirubin WLN in patients with well documented Gilbert's syndrome&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt;&#xD;
             3.0 x institutional upper limit of normal (=&lt; 5 x ULN if known liver metastases)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN, OR&#xD;
&#xD;
          -  Creatinine clearance &gt;= 45 ml/min (24 hour urine creatinine clearance or calculated by&#xD;
             Cockcroft-Gault equation)&#xD;
&#xD;
          -  Any prior radiation must have been completed at least 7 days prior to the start of&#xD;
             study drugs, and patients must have recovered from any acute adverse effects prior to&#xD;
             the start of study treatment&#xD;
&#xD;
          -  Female patients who are not of child-bearing potential and fertile females of&#xD;
             childbearing potential who agree to use adequate contraceptive measures from 2 weeks&#xD;
             prior to the study and until 1 month after study treatment discontinuation, who are&#xD;
             not breastfeeding, and who have a negative serum or urine pregnancy test within 3 days&#xD;
             prior to the start of study treatment&#xD;
&#xD;
          -  Male patients willing to abstain or use barrier contraception (i.e. condoms) for the&#xD;
             duration of the study and for 3 months after treatment stops&#xD;
&#xD;
          -  Willingness and ability to comply with study and follow-up procedures&#xD;
&#xD;
          -  Has read and understands the informed consent form and has given written informed&#xD;
             consent prior to any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of anti-cancer treatment drug =&lt; 21 days or 5 half-lives (whichever is shorter)&#xD;
             prior to the first dose of AZD1775; for drugs for which 5 half-lives is =&lt; 21 days, a&#xD;
             minimum of 10 days between termination of the prior treatment and administration of&#xD;
             AZD1775 treatment is required&#xD;
&#xD;
          -  Previous radiation therapy completed =&lt; 7 days prior to the start of study drugs&#xD;
&#xD;
          -  Major surgical procedures =&lt; 28 days of beginning study treatment, or minor surgical&#xD;
             procedures =&lt; 7 days; no waiting period required following port-a-cath or other&#xD;
             central venous access placement&#xD;
&#xD;
          -  Grade &gt; 1 toxicity from prior therapy (except alopecia or anorexia)&#xD;
&#xD;
          -  Patient has an inability to swallow oral medications; Note: patient may not have a&#xD;
             percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral&#xD;
             nutrition (TPN)&#xD;
&#xD;
          -  No other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer&#xD;
             therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy&#xD;
             or other novel agent is to be permitted while the patient is receiving study&#xD;
             medication; patients on luteinizing hormone-releasing hormone (LHRH) analogue&#xD;
             treatment for more than 6 months are allowed entry into the study and may continue at&#xD;
             the discretion of the investigator&#xD;
&#xD;
          -  Known malignant central nervous system (CNS) disease other than neurologically stable,&#xD;
             treated brain metastases - defined as metastasis having no evidence of progression or&#xD;
             hemorrhage for at least 2 weeks after treatment; must be off any systemic&#xD;
             corticosteroids for the treatment of brain metastases for at least 14 days prior to&#xD;
             enrollment; patients with known brain metastases should be excluded from this clinical&#xD;
             trial because of their poor prognosis and because they often develop progressive&#xD;
             neurologic dysfunction that would confound the evaluation of neurologic and other&#xD;
             adverse events&#xD;
&#xD;
          -  Any known hypersensitivity or contraindication to the components of the study drug&#xD;
             AZD1775&#xD;
&#xD;
          -  Patient has had prescription or non-prescription drugs or other products known to be&#xD;
             sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index,&#xD;
             or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued&#xD;
             2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after&#xD;
             the last dose of study drug; co-administration of aprepitant or fosaprepitant during&#xD;
             this study is prohibited; the use of sensitive substrates of CYP3A4, such as&#xD;
             atorvastatin, simvastatin and lovastatin, is also prohibited in this study;&#xD;
             transporter studies (in vitro) have shown that AZD1775 is an inhibitor of breast&#xD;
             cancer resistance protein (BCRP); herbal preparations are not allowed throughout the&#xD;
             study; these herbal medications include but are not limited to: St. John's wort, kava,&#xD;
             ephedra (ma hung), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto&#xD;
             and ginseng; patients should stop using these herbal medications 7 days prior to first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Any of the following cardiac diseases currently or within the last 6 months as defined&#xD;
             by New York Heart Association (NYHA) &gt;= class 2&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Acute myocardial infarction&#xD;
&#xD;
               -  Conduction abnormality not controlled with pacemaker or medication&#xD;
&#xD;
               -  Significant ventricular or supraventricular arrhythmias (patients with chronic&#xD;
                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities&#xD;
                  are eligible)&#xD;
&#xD;
               -  AZD1775 should not be given to patients who have a history of Torsades de pointes&#xD;
                  unless all risk factors that contributed to Torsades have been corrected; AZD1775&#xD;
                  has not been studied in patients with ventricular arrhythmias or recent&#xD;
                  myocardial infarction&#xD;
&#xD;
          -  Mean resting corrected QT (QTc) interval using the Fridericia formula (QTcF) &gt; 450 ms&#xD;
             (i.e., grade 1 or higher) for males and &gt; 470 ms for females on electrocardiogram&#xD;
             (ECG) prior to initiation of study treatment obtained from 3 electrocardiograms (ECGs)&#xD;
             obtained 2-5 minutes apart at study entry, or history of congenital long QT syndrome&#xD;
&#xD;
               -  If baseline QTc on screening ECG is &gt; 450 ms for males or &gt; 470 ms for females:&#xD;
&#xD;
                    -  Check potassium and magnesium serum levels&#xD;
&#xD;
                    -  Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to&#xD;
                       confirm QTcF interval&#xD;
&#xD;
               -  For patients with baseline heart rate (HR) &lt; 60 bpm or &gt; 100 bpm, manual&#xD;
                  measurement of QT interval by cardiologist is required, with Fridericia&#xD;
                  correction applied to that manual measurement to determine the QTc for&#xD;
                  eligibility consideration&#xD;
&#xD;
               -  Note: For patients with HR 60-100 bpm, manual measurement of QTc interval is NOT&#xD;
                  required&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant or breastfeeding women; pregnant women are excluded from this study because&#xD;
             AZD1775 is WEE1 inhibitor with the potential for teratogenic or abortifacient effects;&#xD;
             because there is an unknown but potential risk for adverse events in nursing infants&#xD;
             secondary to treatment of the mother with AZD1775, breastfeeding should be&#xD;
             discontinued if the mother is treated with AZD1775&#xD;
&#xD;
          -  Prior treatment with WEE1 inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul R Aggarwal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Arash Rezazadeh Kalebasty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Devalingam Mahalingam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Walter M. Stadler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Comprehensive Cancer Center at Silver Cross</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Walter M. Stadler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine-Orland Park</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Walter M. Stadler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joaquina C. Baranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joaquina C. Baranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joaquina C. Baranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ana D. De Jesus Acosta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>617-724-5200</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey I. Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey I. Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Christian Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CancerTrials@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Victor R. Adorno Febles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Anuradha Krishnamurthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brian I. Rini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Brian I. Rini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-632-6789</phone>
      <email>askmdanderson@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jordi Rodon Ahnert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adavosertib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

